Company Overview and News

 
Govt stake in Allahabad Bank goes up by 7.6%

3h moneycontrol
Government's stake in the Allahabad Bank has increased by 7.6 percent post allotment of equity shares on preferential basis, the state-owned lender said.
532480 ALBK

 
Government stake in Allahabad Bank goes up by 7.6 per cent

4h financialexpress
Government’s stake in the Allahabad Bank has increased by 7.6 per cent post allotment of equity shares on preferential basis, the state-owned lender said Monday. The preferential allotment of shares is against infusion of Rs 1,790 crore by the government in the bank. Post allotment of the equity shares, the shareholding of the government has gone up to 79.41 per cent in the bank.
532480 ALBK

 
Allahabad Bank - Allotment of Securities

7h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532480 ALBK

 
Gammon sells Mumbai land in Dombivali for ₹230 crore

2018-10-13 livemint
Mumbai: Debt-laden Mumbai-based civil engineering company Gammon India Ltd has sold 50 acres of land in Mumbai’s suburban Dombivali to real estate firm Runwal group for around ₹ 230 crore as part of an asset monetization plan, according to two people aware of the development who asked not to be named.
ICICIBANK GAMMONIND 532174 IBN 532480 509550 ALBK

 
RBI#39;s corrective action on 12 banks limited losses, saved taxpayer money: Viral Acharya

2018-10-12 moneycontrol
Prompt Corrective Action (PCA) imposed on 12 banks has limited their losses and saved taxpayer money, according to the central bank’s Deputy Governor Viral Acharya.
IOB 500116 UDBKL IDBI ALBK UBLS 532505 532179 532388 532121 CRPKY UBLA 532480 CORPBANK UCOBANK DENABANK

 
From Tata to Satyam, the shocking exits of top company execs that rocked corporate India

2018-10-09 moneycontrol
The resignation of CEO and MD of ICICI Bank Chanda Kochhar, amid conflict of interest allegations, shocked the banking sector recently. A whistle-blower had had alleged that ICICI Bank granted loans to Videocon Group, whose promoter Venugopal Dhoot had investments in NuPower Renewables, owned by the banker's husband Deepak Kochhar. The incident has brought back memories of top company executives who have stepped down over controversies.
YESBANK AXB IBN ALBK 532648 YYBKY 532215 AXBKY AXBA ICICIBANK 5225 PNJZY 532461 AXISBANK 532174 532480 PNB Q0F IHHHF

 
Sandeep Bakshi dons a heavy hat after Chanda Kochhar#39;s exit from ICICI Bank

2018-10-04 moneycontrol
The exit of Chanda Kochhar as the chief executive may augur well for the country's biggest private bank, by bringing an end to the uncertainty at the top leadership. However, ICICI Bank’s board and Sandeep Bakhshi, Kochhar's successor, may have a lot to prove on the corporate governance and business functioning from here on.
ICICIBANK 532174 IBN 532480 ALBK

 
D-Street Buzz: Over 300 stocks hit fresh 52-week low on NSE; IT gains with Infibeam up 11%, realty stocks bleed

2018-09-24 moneycontrol
It is Monday mayhem on Dalal Street which is witnessing continued bloodbath as the Indian stock market is down 1.5 percent. The Nifty50 is down over 170 points and is trading below the 11,ooo mark while the Sensex is trading lower by 500 points at 36,328.
SWANENERGY TCHQY 532834 532832 532755 535789 532480 CAMLINFIN EICHERMOT CLNDY ASHOKLEY EXIDEIND RELCAPITAL 511072 ALBK JETAIRWAYS YYBKY 517334 AKLD 531213 TECHM DHFL EXQDY TCS COALINDIA AKLS IBREALEST 533271 533150 532617 533273 ASHOKA DELTAMAGNT TTNQY 533278 505200 MOZTY 532540 532187 MANAPPURAM 500477 503100 500111 YESBANK ECQRY PHOENIXLTD INDUSINDBK IDKQY 532648 504286 IBULHSGFIN OBZIY GODREJPROP OBEROIRLTY MOTHERSUMI 500086 503310

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...